p3

Cambridge Healthtech Institute’s 6th Annual

Engineering Next-Generation Cancer Immunotherapies

New Protein Engineering Science to Support the Development of Novel Immunotherapeutics and Treatment Combinations

January 20-21, 2020

Part of the Antibody Therapeutics pipeline

Based on the clinical successes of checkpoint inhibitors, the industry is now directing its attention to combination treatments, single agent therapeutics with multiple modes of action, confronting resistance mechanisms, reducing toxicity and the persistent challenge of solid tumors. Cambridge Healthtech Institute’s 6th Annual Engineering Next-Generation Cancer Immunotherapies conference provides a forum in which research scientists can discuss the contributions of protein engineering to the discovery and development of novel biotherapeutics in the IO space.

Preliminary Agenda

DISCOVERY OF IO COMBINATIONS WITH ADDITIVE EFFECTS AND SYNERGISTIC BIOLOGY

KEYNOTE PRESENTATION: Lessons Learned from Combination Trials; What Strategies are Emerging, and What Does This Mean for the Future Course of IO Drug Development?

Shahram Salek-Ardakani, PhD, Senior Director, Cancer Immunology, Pfizer

Enhancing Tumor Targeting Antibodies Through Immunostimulation

Sean H. Lim, PhD, Associate Professor, Haematological Oncology, University of Southampton, United Kingdom

ENGINEERING CONSIDERATIONS FOR NEW IO MODALITIES

Bispecific Antibody and Cytokine Engineering Strategies to Enhance T Cell Activation

Michael Hedvat, PhD, Group Leader, Xencor

Directing T Cell Phenotype and Metabolism During Large-Scale Expansion

Kathryn Henckels, PhD, Senior Scientist, Process Development, Amgen

Rapid Selection and Identification of Functional CD8+ T Cell Epitopes from Large Peptide-Coding Libraries

Govinda Sharma, PhD, Postdoctoral Fellow, Genome Sciences Center, BC Cancer Research Center, Canada

TUMOR SPECIFICITY AND REGIONAL DELIVERY

A Coiled-Coil Masking Domain for Selective Activation of Therapeutic Antibodies

Matthew Levengood, PhD, Principal Scientist, Protein Sciences Seattle Genetics

Novel Antibody Engineering to Improve the Therapeutic Index of Solid Tumor Targeting Antibodies

Hitoshi Katada, PhD, Research Scientist, Biologics Discovery, Chugai Pharmaceutical Co., Ltd., Japan

ENGINEERING CHALLENGES FOR NOVEL CAR T CONFIGURATIONS AND COMBINATIONS

GPC3 as a CAR T Cell Therapy Target in Cancer

Mitchell Ho, PhD, Senior Investigator, National Cancer Institute, NIH

Screening Technology to Identify and Isolate CAR T Molecules in the Ultimate Cellular Therapeutic Format

Tony Cooper, CEO and Co-Founder, Javelin Oncology

Development and Engineering of Generic CAR T Cells

Roy Lobb, PhD, Director and Cofounder, Aleta Biotherapeutics

 

TARGETING THE TUMOR MICROENVIRONMENT WITH THERAPEUTIC PROTEINS

Antibody-Tagged Nanoparticles Addressing the Enhanced Permeability and Retention (EPR) Effect

Lance L. Munn, PhD, Associate Biologist, Tumor Biology, Massachusetts General Hospital

Engineering pH-Dependent Antibody Binding for Selective Targeting of Solid Tumors

Traian Sulea, PhD, Principal Research Officer, Human Health Therapeutics, National Research Council Canada

Exploiting the ECM as a Therapeutic Target in Disease

Noor Jailkhani, PhD, Postdoctoral Fellow, Koch Institute for Integrative Cancer Research, MIT

Epitope and Fc-Mediated Cross-Linking are Critical for MoA of 4-1BB Antibodies: Anti-Tumor Efficacy vs. Liver Toxicity

Hamsell Alvarez, PhD, Principal Research Scientist, Immuno-Oncology Discovery, AbbVie



* The program is subject to change without notice, due to unforeseen reason.

Choose your language
Japanese
Traditional Chinese
Simplified Chinese
Korean


Update History
2019/08/23
Sponsor updated




2020 Conferences & Training Seminars